CSL Limited announced that its subsidiary, CSL Seqirus, and Vaccine Industrial Company have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to localize the manufacturing of cell-based seasonal and pandemic influenza vaccines in Saudi Arabia. Under the finalized agreement, CSL Seqirus will provide its cell-based influenza vaccines and collaborate with Vaccine Industrial Company to localize production at the new Sudair City facility. The agreement also includes provisions for establishing pre-pandemic vaccine stockpiles and an Advance Purchase Agreement to secure pandemic vaccines for the broader population. The local manufacturing facility is expected to begin operations from 2028.